Business
Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025
Akeso Inc. (9926.HK) ("the Company") will hold a conference call to discuss its full-year 2024 results on Monday, March 31, 2025, at the following times:
About this update from Akeso, Inc.
[{"type":"text","content":"HONG KONG, March 28, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("the Company") will hold a conference call to discuss its full-year 2024 results on Monday, March 31, 2025, at the following times:","length":210,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"20:00-21:00 (Hong Kong/China/Singapore)","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"13:00-14:00 (London)","length":20,"tagName":"p"}]},{"val":[{"type":"text","content":"08:00-09:00 (New York)","length":22,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":81,"olType":false},{"type":"text","content":"During the call, Akeso's management team, including:","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Michelle Xia (Chairwoman, President & CEO)","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Baiyong Li (Chief Scientific Officer)","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Bing C. Wang (Chief Financial Officer)","length":42,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":133,"olType":false},{"type":"text","content":"will present an overview of the Company's financial performance for the full year of 2024 and provide insights into the outlook for 2025. The management team will also discuss recent developments, update on the progress of its key innovative pipelines—including bispecific antibodies cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), CD47 monoclonal antibody, ADC, and bispecific ADC —and outline its strategic direction moving forward.","length":445,"tagName":"p"},{"type":"text","content":"Call Details:","length":13,"tagName":"p"},{"type":"text","content":"Hosted by: Sean Wu, Morgan Stanley ResearchLanguage: EnglishRegistration: Investors can pre-register via:https://morganstanley.zoom.us/meeting/register/XGiajcA3TmCmsIXVbZndKQ or contact your Morgan Stanley sales representative.","length":230,"tagName":"p"},{"type":"text","content":"About Akeso","length":11,"tagName":"p"},{"type":"text","content":"Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation sy...